BCAB BioAtla, Inc.
USHealthcareAs of 2026-07-10 16:00
Why BCAB matters now
BioAtla, Inc. (BCAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.82 with +2.69% on the session and $4.8M in market capitalization; recent performance reads 1-month -5.56% and YTD -87.13%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-6.3M, and EPS of $-4.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -806.7%.
The latest indexable market news headline is "Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $250.00; recent insider activity includes Sievers Eric filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.15
P/S
2.30
EV/EBITDA
-0.18
DCF Value
$-4.97
FCF Yield
-806.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
106.0%
Operating Margin
-2525.0%
Net Margin
-2530.8%
ROE
166.7%
ROA
-590.9%
ROIC
477.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-6.3M | $-4.22 |
| Q4 2025 | $2.0M | $-9.8M | $-8.00 |
| FY 2025 | $2.0M | $-59.6M | $-50.50 |
| Q3 2025 | $0.00 | $-15.8M | $-13.50 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$250.00
Target (Median)
$250.00
Target Range
$250.00 - $250.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.77
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.